Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Sandip Patel

    TitleAssistant Clinical Professor
    SchoolUniversity of California, San Diego
    DepartmentMedicine
    vCardDownload vCard

      Collapse Overview 

      Collapse ORNG Applications 
      Collapse Websites
      Collapse Faculty Mentoring
      Collapse Twitter

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Goodman AM, Kato S, Bazhenova L, Patel S, Frampton GM, Miller V, Stephens PJ, Daniels GA, Kurzrock R. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 Aug 23. PMID: 28835386.
        View in: PubMed
      2. Sharabi A, Kim SS, Kato S, Sanders PD, Patel S, Sanghvi P, Weihe E, Kurzrock R. Exceptional Response to Nivolumab and Stereotactic Body Radiation Therapy (SBRT) in Neuroendocrine Cervical Carcinoma with High Tumor Mutational Burden: Management Considerations from the Center For Personalized Cancer Therapy at UC San Diego Moores Cancer Center. Oncologist. 2017 Jun; 22(6):631-637. PMID: 28550027.
        View in: PubMed
      3. Schwaederlé MC, Patel S, Husain H, Ikeda M, Lanman RB, Banks KC, Talasaz A, Bazhenova L, Kurzrock R. Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma. Clin Cancer Res. 2017 Sep 01; 23(17):5101-5111. PMID: 28539465.
        View in: PubMed
      4. Khagi Y, Kurzrock R, Patel S. Next generation predictive biomarkers for immune checkpoint inhibition. Cancer Metastasis Rev. 2017 Mar; 36(1):179-190. PMID: 27873079.
        View in: PubMed
      5. Goodman A, Patel S, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev Clin Oncol. 2017 Apr; 14(4):203-220. PMID: 27805626.
        View in: PubMed
      6. Ikeda S, Goodman AM, Cohen PR, Jensen TJ, Ellison CK, Frampton G, Miller V, Patel S, Kurzrock R. Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy. NPJ Genom Med. 2016; 1. PMID: 27942391.
        View in: PubMed
      7. Beg MS, Azad NS, Patel S, Torrealba J, Mavroukakis S, Beatson MA, Wang XP, Arlen PM, Morse MA. A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer. Cancer Chemother Pharmacol. 2016 Sep; 78(3):577-84. PMID: 27449137.
        View in: PubMed
      8. Schwaederle M, Husain H, Fanta PT, Piccioni DE, Kesari S, Schwab RB, Patel S, Harismendy O, Ikeda M, Parker BA, Kurzrock R. Use of Liquid Biopsies in Clinical Oncology: Pilot Experience in 168 Patients. Clin Cancer Res. 2016 Nov 15; 22(22):5497-5505. PMID: 27185373.
        View in: PubMed
      9. Patel S, Schwaederle M, Daniels GA, Fanta PT, Schwab RB, Shimabukuro KA, Kesari S, Piccioni DE, Bazhenova LA, Helsten TL, Lippman SM, Parker BA, Kurzrock R. Molecular inimitability amongst tumors: implications for precision cancer medicine in the age of personalized oncology. Oncotarget. 2015 Oct 20; 6(32):32602-9. PMID: 26418953; PMCID: PMC4741715.
        View in: PubMed, PubMed Central
      10. Osada T, Patel S, Hammond SA, Osada K, Morse MA, Lyerly HK. CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. Cancer Immunol Immunother. 2015 Jun; 64(6):677-88. PMID: 25742933.
        View in: PubMed
      11. Patel S, Kurzrock R. PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy. Mol Cancer Ther. 2015 Apr; 14(4):847-56. PMID: 25695955.
        View in: PubMed
      12. Patel S, Osada T, Lyerly HK, Morse MA. Designing effective vaccines for colorectal cancer. Immunotherapy. 2014; 6(8):913-26. PMID: 25313570.
        View in: PubMed
      13. Patel S, Bristol A, Saric O, Wang XP, Dubeykovskiy A, Arlen PM, Morse MA. Anti-tumor activity of a novel monoclonal antibody, NPC-1C, optimized for recognition of tumor antigen MUC5AC variant in preclinical models. Cancer Immunol Immunother. 2013 Jun; 62(6):1011-9. PMID: 23591984.
        View in: PubMed
      Sandip's Networks
      Concepts
      Derived automatically from this person's publications.
      See all (64) concept(s)
      _
      Co-Authors
      People in Profiles who have published with this person.
      See all (18) people
      _
      Similar People
      People who share similar concepts with this person.
      See all (60) people
      _
      Same Department
      Search Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _